# US 2020/0399327 A1 · Methods for treating psychiatric disorders or symptoms thereof using ncam peptide mimetics > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 2020/0399327 A1 - Document ID: US20200399327A1 - Status: Published application - Kind: A1 - Application number: 16/784,866 - Filed: 2020-02-07 - Published: 2020-12-24 - Earliest claimed: 2012-06-05 - Assignees: The Board of Trustees of the Leland Stanford Junior University - Applicants: The Board of Trustees of the Leland Stanford Junior University - Inventors: Huda AKIL; Stanley J. WATSON; Cortney TURNER - Web page: https://patentgrep.com/patent/US20200399327A1 ## CPC - C07K 14/435: from animals; from humans - A61K 38/18: Growth factors; Growth regulators - A61P 25/00: Drugs for disorders of the nervous system - A61P 25/22: Anxiolytics - A61P 25/24: Antidepressants - A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia - C07K 7/06: having 5 to 11 amino acids - C07K 7/08: having 12 to 20 amino acids (gastrins C07K14/595; somatostatins C07K14/655; melanotropins C07K14/68) - C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00) - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS ## Abstract The present invention provides methods for treating or alleviating one or more symptoms of depression and/or anxiety in a subject comprising administering an effective amount of an NCAM peptide mimetic to the subject. The symptoms of depression and/or anxiety are typically observed in or associated with a neurological condition. The present invention also provides methods for treating a neurological condition such as a psychiatric disorder in a subject comprising administering an effective amount of an NCAM peptide mimetic to the subject. ## Claims ### Claim 1 A method for treating and/or alleviating one or more symptoms of depression and/or anxiety in a subject comprising administering a therapeutically effective amount of an NCAM peptide mimetic to the subject. ### Claim 2 (depends on 1) The method of claim 1, wherein the subject suffers from a neurological condition. ### Claim 3 (depends on 2) The method of claim 2, wherein the neurological condition comprises a psychiatric disorder. ### Claim 4 (depends on 3) The method of claim 3, wherein the psychiatric disorder comprises a mood disorder or anxiety. ### Claim 5 (depends on 4) The method of claim 4, wherein the mood disorder comprises depression or bipolar disorder. ### Claim 6 (depends on 1) The method of claim 1, wherein the NCAM peptide mimetic comprises a compound of Formula I or a pharmaceutically acceptable salt thereof: (Zn-Lm)q (I), wherein Z is an individually selected peptide comprising the amino acid sequence QQGKSKA, DVRRGIKKTD, or variants thereof, L is individually selected from the group consisting of optionally substituted lipophilic substituents, optionally substituted linkers, and optionally substituted spacers; n is an individually selected integer from about 1 to 6; m is an individually selected integer from about 0 to 6; and q is an individually selected integer from about 1 to 4. ### Claim 7 (depends on 6) The method of claim 6, wherein Z independently comprises about 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 amino acid residues. ### Claim 8 (depends on 6) The method of claim 6, wherein the compound is a monomer or a multimer. ### Claim 9 (depends on 8) The method of claim 8, wherein the multimer is a dimer, tetramer, or dendrimer, and wherein Z is the same peptide or different peptides. ### Claim 10 (depends on 6) The method of claim 6, wherein Z is independently selected from the group consisting of VAENQQGKSKA, EVYVVAENQQGKSKA, and variants thereof. ### Claim 11 (depends on 6) The method of claim 6, wherein the compound has the following structure: ### Claim 12 (depends on 6) The method of claim 6, wherein the compound is a monomer and Z consists of the amino acid sequence EVYVVAENQQGKSKA (“FGLm”). ### Claim 13 (depends on 6) The method of claim 6, wherein the compound has the following structure: ### Claim 14 (depends on 6) The method of claim 6, wherein the compound is a dendrimer having four copies of the amino acid sequence DVRRGIKKTD coupled to a three-lysine-containing backbone (“plannexin”). ### Claim 15 (depends on 1) The method of claim 1, wherein the NCAM peptide mimetic is administered with a pharmaceutically acceptable carrier. ### Claim 16 (depends on 1) The method of claim 1, wherein the NCAM peptide mimetic is administered via a route selected from orally, nasally, topically, subcutaneously, intravenously, intraperitoneally, intrathecally, intracerebroventricularly, and by inhalation. ### Claim 17 (depends on 1) The method of claim 1, wherein the therapeutically effective amount of the NCAM peptide mimetic comprises a dose of between about 0.001 mg/kg to about 1,000 mg/kg per day. ### Claim 18 (depends on 1) The method of claim 1, wherein the NCAM peptide mimetic substantially relieves one or more of the symptoms of depression and/or anxiety in the subject for about 1 week or more after the administration. ### Claim 19 (depends on 1) The method of claim 1, wherein the NCAM peptide mimetic substantially relieves one or more of the symptoms of depression and/or anxiety in the subject within about 1 day to about 14 days after the administration. ### Claim 20 (depends on 1) The method of claim 1, wherein the therapeutically effective amount of the NCAM peptide mimetic is an amount that is sufficient to decrease anxiety (anxiolytic effect) in the subject. ### Claim at position 21 21-41. (canceled)